Neurocrine Biosciences (NBIX)

P/S ratio as of November 2026 (TTM): 4.62

According to Neurocrine Biosciences 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.64. At the end of 2023 the company had a P/S ratio of 6.86.

P/S ratio history for Neurocrine Biosciences from 2001 to 2023

PS ratio at the end of each year

Year	P/S ratio	Change
2023	6.86	-11.06%
2022	7.71	8.2%
2021	7.13	-16.75%
2020	8.56	-31.97%
2019	12.6	-12.4%
2018	14.4	-66.18%
2017	42.5	-81.05%
2016	224	-9.2%
2015	247
2014	N/A	-100%
2013	216	2204.11%
2012	9.35	54.16%
2011	6.07	-51.52%
2010	12.5	-69.11%
2009	40.5	30.41%
2008	31.1	-78.11%
2007	142	1310.15%
2006	10.1	-46.46%
2005	18.8	-11.08%
2004	21.1	52.7%
2003	13.8	-82.15%
2002	77.6	105.49%
2001	37.8

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Pfizer PFE	2.63	-43.13%	🇺🇸 USA
AbbVie ABBV	7.87	70.15%	🇺🇸 USA
Eli Lilly LLY	14.8	219.05%	🇺🇸 USA
Repligen RGEN	13.8	198.49%	🇺🇸 USA
Athersys ATHX	10.4	125.19%	🇺🇸 USA
ANI Pharmaceuticals ANIP	1.56	-66.37%	🇺🇸 USA
Palatin Technologies PTN	0.9307	-79.88%	🇺🇸 USA
Royalty Pharma RPRX	15.3	229.96%	🇬🇧 UK

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Neurocrine Biosciences (NBIX)

P/S ratio as of November 2026 (TTM): 4.62